6390.5000 -37.00 (-0.58%)
NSE Dec 29, 2025 15:31 PM
Volume: 245.0K
 

Deven Choksey
Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.
Divi's Laboratories .. has an average target of 6432.50 from 6 brokers.
More from Divi's Laboratories Ltd.
Recommended